FeedsNon-Hodgkin's Lymphoma (NHL) Outcomes
The survival graph below illustrates outcomes of unrelated donor hematopoietic cell transplants (bone marrow, PBSC, or cord blood or marrow transplants — BMT) coordinated by the National Marrow Donor Program (NMDP) for adult patients.
Figure 1 shows that there is no significant difference in five-year survival for adult patients (> 18 years of age) undergoing non-myeloablative transplantation for non-Hodgkin's lymphoma (NHL) regardless of stem cell source (log-rank p-value = 0.92). Most NHL patients who receive an unrelated donor or cord blood transplant are transplanted at the time the disease recurs.
Non-Hodgkin's lymphoma: Survival of adult non-myeloablative transplant patients by stem cell source 1998-2006. (NMDP data)
View larger version Download slide (PPT)
| Adult non-myeloablative transplants facilitated by the NMDP, 1998-2006 | ||
| Stem Cell Source | # of Transplants | Kaplan-Meier 5-Year Survival* |
| Marrow | 138 | 39% ± 9% |
| PBSC | 254 | 37% ± 9% |
- For additional NHL transplant outcomes, see Transplant Outcomes by Disease and Disease Stage.
- For information for patients, see Non-Hodgkin's Lymphoma (NHL).
- For additional NMDP outcomes data, see NMDP Transplant Outcomes.
